PL2200642T3 - Preparaty szczepionek meningokokowych - Google Patents

Preparaty szczepionek meningokokowych

Info

Publication number
PL2200642T3
PL2200642T3 PL08838605T PL08838605T PL2200642T3 PL 2200642 T3 PL2200642 T3 PL 2200642T3 PL 08838605 T PL08838605 T PL 08838605T PL 08838605 T PL08838605 T PL 08838605T PL 2200642 T3 PL2200642 T3 PL 2200642T3
Authority
PL
Poland
Prior art keywords
meningitidis
vaccine formulations
lyophilised
meningococcal vaccine
formulation
Prior art date
Application number
PL08838605T
Other languages
English (en)
Inventor
Mario Contorni
Jina Kazzaz
Derek O'hagan
Manmohan Singh
Mildred Ugozzoli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2200642T3 publication Critical patent/PL2200642T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL08838605T 2007-10-19 2008-10-17 Preparaty szczepionek meningokokowych PL2200642T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99959007P 2007-10-19 2007-10-19
PCT/IB2008/003283 WO2009050586A1 (en) 2007-10-19 2008-10-17 Meningococcal vaccine formulations
EP08838605A EP2200642B1 (en) 2007-10-19 2008-10-17 Meningococcal vaccine formulations

Publications (1)

Publication Number Publication Date
PL2200642T3 true PL2200642T3 (pl) 2012-09-28

Family

ID=40428348

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08838605T PL2200642T3 (pl) 2007-10-19 2008-10-17 Preparaty szczepionek meningokokowych

Country Status (20)

Country Link
US (2) US20100285069A1 (pl)
EP (2) EP2200642B1 (pl)
JP (3) JP5701058B2 (pl)
CN (1) CN101951949B (pl)
AT (1) ATE553774T1 (pl)
AU (1) AU2008313424B2 (pl)
BR (2) BRPI0818545A2 (pl)
CA (2) CA2925217A1 (pl)
CO (1) CO6270339A2 (pl)
CY (1) CY1112908T1 (pl)
DK (1) DK2200642T3 (pl)
ES (1) ES2383231T3 (pl)
HR (1) HRP20120433T1 (pl)
MX (2) MX340096B (pl)
NZ (1) NZ584683A (pl)
PL (1) PL2200642T3 (pl)
PT (1) PT2200642E (pl)
RU (2) RU2498815C2 (pl)
SI (1) SI2200642T1 (pl)
WO (1) WO2009050586A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
BRPI0923006A2 (pt) * 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011294776B2 (en) * 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
EA201390341A1 (ru) 2010-09-01 2013-08-30 Новартис Аг Адсорбция иммунопотенциаторов на нерастворимых солях металлов
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
CN104203946B (zh) 2012-03-07 2017-03-22 诺华股份有限公司 免疫上有用的精氨酸盐
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
KR20200077538A (ko) * 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69331495T2 (de) 1992-08-31 2002-10-31 Baxter Healthcare S.A., Wallisellen Impfstoffe gegen neisseria meningitidis gruppe c
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
PT991761E (pt) 1997-08-21 2008-04-28 Staat Nl Verteg Door Min Welzi Mutantes novos de bactérias gram negativas das mucosas e a sua aplicação em vacinas.
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
PT1584685E (pt) * 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261346A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP5074644B2 (ja) * 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 組合わせの髄膜炎菌ｂ／ｃワクチン
EP1741443B1 (en) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
DK1897555T3 (da) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
HU230490B1 (hu) 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
DE60325565D1 (de) 2002-03-26 2009-02-12 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20060110736A1 (en) * 2002-10-07 2006-05-25 John Donnelly Hiv vaccine formulations
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
ATE466875T1 (de) * 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) * 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2588089C (en) * 2004-11-15 2015-06-23 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
CA2601022C (en) 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8156755B2 (en) * 2005-06-03 2012-04-17 Intervet International B.V. Refrigerator for storing vials and cartridge for use in the same
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
US8431160B2 (en) * 2006-02-24 2013-04-30 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines

Also Published As

Publication number Publication date
RU2498815C2 (ru) 2013-11-20
RU2010119947A (ru) 2011-11-27
CA2925217A1 (en) 2009-04-23
PT2200642E (pt) 2012-05-30
AU2008313424B2 (en) 2014-05-22
EP2200642A1 (en) 2010-06-30
MX340096B (es) 2016-06-27
CN101951949B (zh) 2013-10-02
JP5925736B2 (ja) 2016-05-25
JP2013216704A (ja) 2013-10-24
CN101951949A (zh) 2011-01-19
US20100285069A1 (en) 2010-11-11
CY1112908T1 (el) 2016-04-13
US20160228529A1 (en) 2016-08-11
JP2016029108A (ja) 2016-03-03
NZ584683A (en) 2012-05-25
HRP20120433T1 (en) 2012-07-31
WO2009050586A1 (en) 2009-04-23
CO6270339A2 (es) 2011-04-20
MX2010004271A (es) 2010-05-03
BRPI0818545A2 (pt) 2017-07-04
AU2008313424A1 (en) 2009-04-23
BR122016015627A2 (pt) 2018-10-30
EP2462949A2 (en) 2012-06-13
ATE553774T1 (de) 2012-05-15
JP2011500662A (ja) 2011-01-06
ES2383231T3 (es) 2012-06-19
JP5701058B2 (ja) 2015-04-15
EP2462949A3 (en) 2012-09-05
SI2200642T1 (sl) 2012-06-29
CA2702871A1 (en) 2009-04-23
RU2013133864A (ru) 2015-01-27
DK2200642T3 (da) 2012-07-16
EP2200642B1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
HRP20120433T1 (en) Meningococcal vaccine formulations
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
CR10123A (es) Vacuna.
ATE463261T1 (de) Meningokokken-konjugat-impfung
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
ATE512670T1 (de) Meningokokken-konjugat-impfung
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
TW200722101A (en) Novel composition
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
PL2004225T3 (pl) Schematy immunizacji koniugatami meningokokowymi
WO2010067202A3 (en) Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2018042017A3 (en) Vaccines for neisseria gonorrhoeae
MX2015013401A (es) Procedimiento de tratamiento.
Haneberg et al. Can nonliving nasal vaccines be made to work?
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
SG160386A1 (en) Novel composition
AR095579A1 (es) Procedimiento de inmunización